header logo image


Page 11234..1020..»

Archive for the ‘Integrative Medicine’ Category

What is Integrative Medicine? – Andrew Weil, M.D. – DrWeil.com

Wednesday, August 7th, 2024

Andrew Weil, M.D., is the worlds leading proponent of alternative medicine, right? Wrong.

Although this is how the popular media often portrays him, Dr. Andrew Weil is actually the worlds leading proponent of integrative medicine, a philosophy that is considerably different from a blanket endorsement of alternative medicine. To fully understand Dr. Weils advice presented in his website, bestselling books and lectures, and reflected in the daily practice of thousands of physicians worldwide (thanks to the in-depth training acquired at the Andrew Weil Center For Integrative Medicine at the University Of Arizona in Tucson) its important to grasp what integrative medicine is, and is not.

The first step is mastering some basic terms. Using synthetic drugs and surgery to treat health conditions was known just a few decades ago as, simply, medicine. Today, this system is increasingly being termed conventional medicine. This is the kind of medicine most Americans still encounter in hospitals and clinics. Often both expensive and invasive, it is also very good at some things; for example, handling emergency conditions such as massive injury or a life-threatening stroke. Dr. Weil is unstinting in his appreciation for conventional medicines strengths. If I were hit by a bus, he says, Id want to be taken immediately to a high-tech emergency room. Some conventional medicine is scientifically validated, some is not.

Any therapy that is typically excluded by conventional medicine, and that patients use instead of conventional medicine, is known as alternative medicine. Its a catch-all term that includes hundreds of old and new practices ranging from acupuncture to homeopathy to iridology. Generally alternative therapies are closer to nature, cheaper and less invasive than conventional therapies, although there are exceptions. Some alternative therapies are scientifically validated, some are not. An alternative medicine practice that is used in conjunction with a conventional one is known as a complementary medicine. Example: using ginger syrup to prevent nausea during chemotherapy. Together, complementary and alternative medicines are often referred to by the acronym CAM.

Enter integrative medicine. As defined by the National Center for Complementary and Alternative Medicine at the National Institutes of Health, integrative medicine combines mainstream medical therapies and CAM therapies for which there is some high-quality scientific evidence of safety and effectiveness.

In other words, integrative medicine cherry picks the very best, scientifically validated therapies from both conventional and CAM systems. In his New York Times review of Dr. Weils latest book, Healthy Aging: A Lifelong Guide to Your Physical and Spiritual Well-Being, Abraham Verghese, M.D., summed up this orientation well, stating that Dr. Weil, doesnt seem wedded to a particular dogma, Western or Eastern, only to the get-the-patient-better philosophy.

So this is a basic definition of integrative medicine. What follows is the complete one, which serves to guide both Dr. Weils work and that of integrative medicine physicians and teachers around the world:

Integrative medicine is healing-oriented medicine that takes account of the whole person (body, mind, and spirit), including all aspects of lifestyle. It emphasizes the therapeutic relationship and makes use of all appropriate therapies, both conventional and alternative.

The principles of integrative medicine:

Go here to see the original:
What is Integrative Medicine? - Andrew Weil, M.D. - DrWeil.com

Read More...

Integrative Doctor | The Carolina Center for Integrative Medicine

Wednesday, August 7th, 2024

He received his medical degree from Mercer University in Macon, Georgia in 1986 and attended the Pediatric Residency Program at NC Baptist Hospital in Winston-Salem, North Carolina with an emphasis in Preventive Medicine. Later, while serving as Emergency Department Director at hospitals in Rocky Mount and Southport, NC, he began exploring ways to combine conventional medicine with nutrition, botanicals, and other natural therapies as an integral part of clinical medical practice.

Since founding the Carolina Center in 1994, Dr. Pittman has further enhanced his understanding of integrative medicine through clinical training at the Autism Research Institute and the International Lyme and Associated Diseases Societys Physician Training Program.

He has lectured frequently at the UNC School of Medicines Program on Integrative Medicine and presently serves as a member of the states Vector Disease Task Force and was the former President of the North Carolina Integrative Medicine Society. From the beginning, Dr. Pittmans vision for the Center was to bring together multiple healing modalities in order to help patients overcome chronic degenerative illnesses and bolster their health and wellness.

Visit link:
Integrative Doctor | The Carolina Center for Integrative Medicine

Read More...

Spotlight on Wellness: the revolutionary world of integrative and regenerative medicine – Daily Tribune (Philippines)

Wednesday, August 7th, 2024

Spotlight on Wellness: the revolutionary world of integrative and regenerative medicine  Daily Tribune (Philippines)

Follow this link:
Spotlight on Wellness: the revolutionary world of integrative and regenerative medicine - Daily Tribune (Philippines)

Read More...

Skye Bioscience to Host Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” on July 24th

Saturday, July 13th, 2024

SAN DIEGO, July 11, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, today announced that it will host a virtual KOL event entitled “Metabolic Rewiring with CB1 Inhibition” on Wednesday, July 24, 2024, at 9:00 AM ET.

Excerpt from:
Skye Bioscience to Host Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” on July 24th

Read More...

Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board

Saturday, July 13th, 2024

ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the appointment of Glenn C. Yiu, M.D., Ph.D., Professor of Ophthalmology at the University of California, Davis, to its Scientific Advisory Board (SAB), which is comprised of industry-leading retinal physicians who provide medical and scientific expertise and input on the Company’s research and development programs.

Here is the original post:
Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board

Read More...

NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline

Saturday, July 13th, 2024

NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline

View post:
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline

Read More...

Avicanna Subsidiary Completes Export of Aureus Branded CBG into Singapore

Saturday, July 13th, 2024

This marks the first export into Asia, the 18th international market for Aureus branded products and 21st market for all Avicanna products

See original here:
Avicanna Subsidiary Completes Export of Aureus Branded CBG into Singapore

Read More...

Rentschler Biopharma Announces New State-of-the-Art Production Line in Massachusetts is Fully Operational

Saturday, July 13th, 2024

LAUPHEIM, Germany and MILFORD, Mass., July 11, 2024 (GLOBE NEWSWIRE) -- Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, including advanced therapy medicinal products (ATMPs), today announced that the company’s new state-of-the-art production line, formerly known as the Rentschler Biopharma Manufacturing Center (RBMC), in Milford, MA in the U.S. is now fully operational. The company has a major project underway at the new line, with several additional projects in the pipeline, and continues to welcome new projects and clients.

Continued here:
Rentschler Biopharma Announces New State-of-the-Art Production Line in Massachusetts is Fully Operational

Read More...

Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona’s Patented AAV204…

Saturday, July 13th, 2024

CLEVELAND and LONDON, July 11, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a cell and gene therapy company with proprietary adeno-associated virus (AAV)-based capsids, and Beacon Therapeutics, an ophthalmic gene therapy company and Syncona portfolio company, today announced an agreement by which Beacon will evaluate Abeona's patented AAV204 capsid for the development and commercialization of potential gene therapies for select ophthalmology indications.

Go here to read the rest:
Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204...

Read More...

Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association…

Saturday, July 13th, 2024

NEWTON, Mass., July 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (A?Os) for the treatment of Alzheimer’s disease (AD), today announced that the Company will present patient experience and biomarker data from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) at the Alzheimer’s Association International Conference (AAIC®) 2024 taking place in Philadelphia and online from July 28 – Aug. 1, 2024. The posters expand upon biomarker data associated with sabirnetug, methods for detecting levels of sabirnetug in cerebrospinal fluid (CSF), and provide insights on patients’ experiences in the INTERCEPT-AD study to inform future clinical trial considerations for sabirnetug.

Originally posted here:
Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association...

Read More...

Entero Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds

Saturday, July 13th, 2024

BOCA RATON, Fla., July 11, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (“Entero” or the “Company”) (NASDAQ: ENTO), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced it has entered into agreements with certain holders of its existing warrants exercisable for 1,762,674 shares of its common stock, in the aggregate, to exercise their warrants at a reduced exercise price of $1.09 per share, in exchange for new warrants as described below. The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $1,921,315, before deducting financial advisory fees. The reduction in the exercise price of the existing warrants and the issuance of the new warrants was structured as an at-market transaction under Nasdaq rules.

More:
Entero Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds

Read More...

Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product

Saturday, July 13th, 2024

Company has now completed murine and non-murine pivotal nonclinical studies using GMP PALI-2108 drug substance

More here:
Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product

Read More...

Fortrea Appoints Robert Parks as Chief Accounting Officer

Saturday, July 13th, 2024

DURHAM, N.C., July 11, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that Robert “Bobby” Parks has been appointed as chief accounting officer (CAO), responsible for Fortrea’s accounting function, including financial reporting, risk, controls and compliance in accordance with applicable standards, laws and regulations.

Original post:
Fortrea Appoints Robert Parks as Chief Accounting Officer

Read More...

3Daughters Secures $4.7 Million in Oversubscribed Seed Round

Saturday, July 13th, 2024

Funds will support development of game-changing IUD (intrauterine device) for contraception through an IND filing in early 2025 Funds will support development of game-changing IUD (intrauterine device) for contraception through an IND filing in early 2025

Continue reading here:
3Daughters Secures $4.7 Million in Oversubscribed Seed Round

Read More...

Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia…

Saturday, July 13th, 2024

NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, today announced that the company will conduct an investor webcast on Monday, July 15, 2024, at 8:00 AM ET to provide an interim clinical data update on LX2006, an AAVrh10.hFXN gene therapy for the treatment of Friedreich ataxia (FA) cardiomyopathy. The presentation will include an overview of the natural history of FA cardiomyopathy and summary of clinically meaningful endpoints, interim data from Lexeo’s ongoing SUNRISE-FA Phase 1/2 clinical trial (NCT05445323) and the ongoing Weill Cornell Medicine investigator-initiated trial (NCT05302271), as well as an overview of program next steps.

View post:
Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia...

Read More...

California Medicaid Adds TMS Access for 14.8 Million Adolescents and Adults

Saturday, July 13th, 2024

NeuroStar, the first and only TMS treatment cleared for adolescents, now covered by Medi-Cal NeuroStar, the first and only TMS treatment cleared for adolescents, now covered by Medi-Cal

Original post:
California Medicaid Adds TMS Access for 14.8 Million Adolescents and Adults

Read More...

Kane Biotech Signs Worldwide License Agreement with Omni Bioceutical Innovations Inc.

Saturday, July 13th, 2024

First Licensing Agreement for coactiv+™ Scalp Care Line First Licensing Agreement for coactiv+™ Scalp Care Line

Follow this link:
Kane Biotech Signs Worldwide License Agreement with Omni Bioceutical Innovations Inc.

Read More...

Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing

Saturday, July 13th, 2024

SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. (Nasdaq: PSNL) today announced that they have entered into an agreement to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease (MRD). The agreement helps solidify each company’s freedom to operate in the MRD market and broadens patient access to the benefits of MRD testing.

See the original post here:
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing

Read More...

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

Saturday, July 13th, 2024

BOSTON, July 11, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, July 23, 2024 at 10:00 AM ET.

Read the original here:
CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

Read More...

Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA…

Saturday, July 13th, 2024

SALT LAKE CITY, July 11, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced plans to submit a briefing book by July 13 to the U.S. Food and Drug Administration (FDA) in advance of a granted Type C interaction. The purpose of the interaction with the FDA, to occur in the third quarter of 2024, is to receive feedback on the potential path to submission of a new drug application (NDA) for CNM-Au8® as a potential treatment for ALS via the accelerated approval pathway.

Read the original:
Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA...

Read More...

Page 11234..1020..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick